MedTrace Logo

Efficacy of Retreatments With Intravitreal Bevacizumab

NCT00406744 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-06-03

No results posted yet for this study

Summary

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Conditions

  • Age Related Macular Degeneration
  • Choroidal Neovascularization

Interventions

DRUG

Intravitreal injection of Bevacizumab

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Veronica Kon-Jara, MD · Asociación para Evitar la Ceguera en México

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-05-31
Completion
2006-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406744 on ClinicalTrials.gov